Wynzora® Cream is approved and marketed in Italy, Germany, Spain, the United Kingdom, and the United States.SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ...

Wynzora® Cream is approved and marketed in Italy, Germany, Spain, the United Kingdom, and the United States.SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens ...

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone ...

MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has reached a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada through its subsidiary, Paladin Pharma Inc. This ...

Hyphens will pay MC2 a total of EUR2.5 million ($3.6 million), which includes an upfront payment and additional fees. Pharmaceutical and consumer healthcare group Hyphens Pharma International 1J5 has ...

Find patient medical information for Calcipotriene/Betamethasone topical on WebMD including its uses, side effects and safety, interactions, pictures, warnings and ...

With this approval, Glenmark is eligible for 180-days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam, 0.005 per cent |0.064 per cent ...

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

MALVERN, Pa., Nov. 15, 2024 /CNW/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora ® Cream ...